Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Cary Twyman

Neurology Hershey, PA Medical Doctor

NPI 1407803141 CMS profile 108269

30 Hope Dr Ste 1300, Hershey, PA 17033

Open in the dashboard

General payments

$172,284

185 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,640 paid to institutions, not to them · program years 2019–2020

Through program year 2023, Cary Twyman of Hershey, PA is reported in the CMS Open Payments database as having received $172,284 across 185 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $12,640 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $127 1
2022 General $69 1
2021 General $36,944 27
2020 General $24,209 19
2019 General $110,935 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cary Twyman
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Cary Twyman were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Cary Twyman Neurology median Middle half National median
2019 $110,935 $474 $118–$2,177 $163
2020 $24,209 $367 $82–$2,309 $114
2021 $36,944 $438 $104–$2,547 $132
2022 $69 $442 $103–$2,388 $149
2023 $127 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Biogen, Inc. $64,521 45 payments
  2. Genentech USA, Inc. $20,906 15 payments
  3. Genzyme Corporation $20,726 24 payments
  4. Alexion Pharmaceuticals, Inc. $19,367 34 payments
  5. Celgene Corporation $19,198 23 payments
  6. EMD Serono, Inc. $18,386 27 payments
  7. Novartis Pharmaceuticals Corporation $4,922 10 payments
  8. E.R. Squibb & Sons, L.L.C. $4,211 4 payments
  9. Acorda Therapeutics, Inc $34 2 payments
  10. Mallinckrodt Hospital Products Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $124,060 49 payments
  2. Consulting Fee $30,582 15 payments
  3. Travel and Lodging $13,798 38 payments
  4. Food and Beverage $3,701 79 payments
  5. Education $143 4 payments
Products named General payments · program years 2019–2023
  1. OCREVUS $20,906 15 payments
  2. LEMTRADA $20,726 24 payments
  3. VUMERITY $19,083 9 payments
  4. Mavenclad $15,008 20 payments
  5. ZEPOSIA $14,754 18 payments
  6. TECFIDERA $14,466 8 payments
  7. TYSABRI $13,055 10 payments
  8. Ozanimod $8,655 9 payments
  9. Rebif $2,706 4 payments
  10. MAYZENT $2,448 3 payments
  11. Other $405 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record